Immuneering Corporation - Class A — Quarterly Dividends (NASDAQ:IMRX) | MetaTrader

Open full chart

ニュース

Immuneering’s (IMRX) chief business officer buys $24,990 in stock

Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data (NASDAQ:IMRX)

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.55%

Alibaba, Costco among market cap stock movers on Thursday

Costco, Alibaba among market cap stock movers on Thursday

Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Acrivon Therapeutics (NASDAQ:ACRV), Cormedix (NASDAQ:CRMD)

Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings - Acrivon Therapeutics (NASDAQ:ACRV), Acuity (NYSE:AYI)

Why Is Immuneering Stock Trading Lower Today? - Immuneering (NASDAQ:IMRX)

Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Canadian Solar (NASDAQ:CSIQ), Elme (NYSE:ELME)

Stock Market Today: S&P 500, Dow Jones Futures Decline — AZZ, Northrop Grumman, Immuneering In Focus - SPDR S&P 500 (ARCA:SPY)

Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Acrivon Therapeutics (NASDAQ:ACRV), AZZ (NYSE:AZZ)

Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript